| Outcome Measures: |
Primary: Incidence, nature and severity of adverse events, The primary objective of the study is to evaluate the safety and tolerability of single ascending doses of SL liraglutide in subjects with Type II Diabetes Mellitus (T2DM), and the primary outcome measures are therefore the incidence, nature and severity of adverse events, including those that are serious, dose limiting or of special interest., Through study completion, an average of 6 weeks | Secondary: Peak Plasma Concentration (Cmax) for glucose, A secondary objective is to document the pharmacodynamic effect of SL liraglutide through a mixed meal tolerance test (MMTT) following single ascending dosing in treated subjects., 5 hours following administration of the study drug|Area under the plasma concentration versus time curve (AUC) for glucose, A secondary objective is to document the pharmacodynamic effect of SL liraglutide through a mixed meal tolerance test (MMTT) following single ascending dosing in treated subjects., 5 hours following administration of the study drug|Peak Plasma Concentration (Cmax) for C-peptide, A secondary objective is to document the pharmacodynamic effect of SL liraglutide through a mixed meal tolerance test (MMTT) following single ascending dosing in treated subjects., 5 hours following administration of the study drug|Peak Plasma Concentration (Cmax) for insulin, A secondary objective is to document the pharmacodynamic effect of SL liraglutide through a mixed meal tolerance test (MMTT) following single ascending dosing in treated subjects., 5 hours following administration of the study drug|Area under the plasma concentration versus time curve (AUC) for C-peptide, A secondary objective is to document the pharmacodynamic effect of SL liraglutide through a mixed meal tolerance test (MMTT) following single ascending dosing in treated subjects., 5 hours following administration of the study drug|Area under the plasma concentration versus time curve (AUC) for insulin, A secondary objective is to document the pharmacodynamic effect of SL liraglutide through a mixed meal tolerance test (MMTT) following single ascending dosing in treated subjects., 5 hours following administration of the study drug|Insulin secretion rate (ISR), A secondary objective is to document the pharmacodynamic effect of SL liraglutide through a mixed meal tolerance test (MMTT) following single ascending dosing in treated subjects., 5 hours following administration of the study drug|Serum concentration of liraglutide, A secondary objective is to determine the pharmacokinetics (PK) of SL-liraglutide in plasma following single ascending dosing in treated subjects., 5 hours following administration of the study drug
|
